Universität zu Köln

Platten, M., Linnemann, R., Kuemmerle, T., Jung, N., Wyen, C., Ehren, K., Gravemann, S., Gillor, D., Cornely, O. A., Fischer, J., Lehmann, C., Rockstroh, J. K., Faetkenheuer, G. and Vehreschild, J. J. (2014). Clinical course and quality of care in ART-na < ve patients newly presenting in a HIV outpatient clinic. Infection, 42 (5). S. 849 - 858. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-0973

Full text not available from this repository.

Abstract

Little data exist about the quality of care for HIV-infected subjects in Germany. We investigated the clinical course of HIV-infected subjects newly presenting in our HIV outpatient clinic. Antiretroviral therapy (ART)-na < ve HIV-infected subjects presenting between 2007 and 2008 were followed until June 2012. Clinical data and laboratory parameters were collected prospectively and analysed retrospectively. From 281 subjects included, 34 patients (12 %) were lost to follow-up. 247 subjects remained, and 171 patients were followed for 1,497 days [1,121/1,726] (all data: median [interquartile range]). ART was started in 199 patients (81 %) 182 days [44/849] after HIV diagnosis, and all patients were treated according to European guidelines or within clinical trials. The CD4 cell count at first presentation was 320/A mu L [160/500] and declined to 210/A mu L [100/300] at ART start. 12 months thereafter, the CD4 cell count increased to 410/A mu L [230/545]. The HIV RNA was suppressed below 50 copies/mL after 108 days [63/173] in 182 patients (91 %). Initial ART was changed in 71 patients (36 %) after 281 days [99/718], in five patients (7 %) due to virological failure, in 66 patients (93 %) due to other reasons, e.g. side effects or patient's request. Two-thirds of the included patients were followed for more than 3 years, and ART was initiated in 81 % of the patients leading to complete virological suppression in most patients. Compliance of physicians with treatment guidelines was high. Late presentation with a severely compromised immune function remains a problem and impairs the otherwise good prognosis of HIV infection.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Platten, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Linnemann, R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuemmerle, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Jung, N. UNSPECIFIED UNSPECIFIED UNSPECIFIED Wyen, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ehren, K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gravemann, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Gillor, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cornely, O. A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehmann, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rockstroh, J. K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Faetkenheuer, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Vehreschild, J. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-427726
DOI:	10.1007/s15010-014-0646-9
Journal or Publication Title:	Infection
Volume:	42
Number:	5
Page Range:	S. 849 - 858
Date:	2014
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1439-0973
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS; COMBINATION; INITIATION; TENOFOVIR; MORTALITY Multiple languages Infectious Diseases Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/42772